Pfizer Inc. (NYSE:PFE) has divested a $3.3 billion stake in Haleon (NYSE:HLN), reducing its holding in the British consumer healthcare company. What Happened: The transaction occurred on Monday, cutting Pfizer’s shareholding from 22.

Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6%

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.

Pfizer sells further shares in Sensodyne maker Haleon for £2.4bn - Haleon was formed in 2019 by the merger of the consumer healthcare businesses of GSK and US rival Pfizer, but was spun out and floated in 2022.

Pfizer has offloaded a £2.43billion stake in consumer health spin-out Haleon, which said it would buy back £230million of the shares. FTSE 100-listed Haleon, which makes Panadol painkillers and Sensodyne toothpaste, said it had bought the shares at 308p each.

Pfizer has raised about US$3.2 billion from the sale of Haleon shares, as it further reduces its stake in the UK consumer health company. Read more at The Business Times.

Pfizer has sold a stake in British consumer healthcare group Haleon worth about $3.26 billion, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil painkillers to 15% from 22.

Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical company sold 640 million ordinary shares in British consumer-healthcare business Haleon at 380 pence a share.

Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.

Pfizer's stake sale in British consumer healthcare company Haleon has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.

Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual divestment strategy. Read more here.